Clinical Trials Logo

Hepatitis E Virus Infection clinical trials

View clinical trials related to Hepatitis E Virus Infection.

Filter by:
  • None
  • Page 1

NCT ID: NCT06306196 Not yet recruiting - Clinical trials for Hepatitis E Virus Infection

Immunogenicity and Safety of Hecolin® in HIV Positive/Negative Adults and in Children

Start date: April 2024
Phase: Phase 2
Study type: Interventional

The primary goal of this clinical trial is to demonstrate non-inferiority of 30 µg of Hecolin® in healthy children, compared to healthy adults as measured by seroresponse rates (SR) of anti-HEV IgG titers, 4 weeks after 3 doses (0, 1 and 6 months) and to assess and descriptively compare safety profile data intra and inter age Strata. As secondary objectives, Geometric Mean Concentration (GMC) of anti-HEV IgG ELISA will be evaluated 4 weeks after 3 doses (0, 1 and 6 months) and 4 weeks after 2 doses (0- and 6-months dose) in healthy children. SR and GMC will also be evaluated 24 weeks after 3 doses and 2 doses. The immune response will be compared among adult participants between HIV positive and HIV negative individuals and between virally suppressed and virally unsuppressed HIV positive individuals

NCT ID: NCT05415345 Active, not recruiting - Clinical trials for Human Papilloma Virus Infection Type 16

Immunogenicity and Safety of Co-immunization With Cecolin and Hecolin

Start date: October 25, 2021
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the immunogenicity and safety of co-immunization with recombinant human papillomavirus bivalent (Types 16,18) vaccine (Escherichia coli) and Hepatitis E vaccine (Escherichia coli)

NCT ID: NCT05300425 Recruiting - Leptospirosis Clinical Trials

Seroprevalence of Leptospirosis in Val Müstair, Switzerland

Start date: March 3, 2022
Phase:
Study type: Observational

Human leptospirosis is a zoonotic disease caused by bacteria of the genus Leptospira. Due to its frequent inapparent course or mild severity with unspecific symptoms and limited availability of diagnostic laboratories the incidence of leptospirosis is likely to be underestimated. The hospital of Val Müstair is the major healthcare provider of a rural mountain valley in the canton of Graubünden/ Switzerland with approximately 1500 inhabitants. A relevant prevalence of Leptospira spp. antibodies in the population of the Val Müstair due to its geographic and social risk profile for Leptospira infection, namely the close contact of the population to both livestock and wildlife in agriculture and hunting is estimated. The aim of this study is to analyze the burden of this disease in order to evaluate the need of preventive measures. In addition, seroepidemiological data for the Hepatitis E virus (HEV) and for tularemia will be collected.

NCT ID: NCT02645955 Completed - Clinical trials for Hepatitis E Virus Infection

Epidemiological Study of Hepatitis E Virus in Maintenance Hemodialysis Patients

MHD HEV
Start date: May 2016
Phase:
Study type: Observational [Patient Registry]

Primary Purpose: 1. Evaluate the prevalence and incidence of HEV infection in MHD patients. 2. Compare differences of the prevalence and incidence between the MHD patients and the control. . Secondary purpose: Analyze risk factors of HEV infection.